BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fabris P, Betterle C, Floreani A, Greggio NA, de Lazzari F, Naccarato R, Chiaramonte M. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet. 1992;340:548. [PMID: 1354296 DOI: 10.1016/0140-6736(92)91744-s] [Cited by in Crossref: 127] [Cited by in F6Publishing: 108] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Wang L, Chen K, Wang M, Lv Z, Gu W, Wang X, Ni Q, Mu Y. Characteristics of Interferon-Associated Diabetes Mellitus in Past 30 Years: A Review. Horm Metab Res 2022;54:145-52. [PMID: 35276739 DOI: 10.1055/a-1749-5716] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chee YJ, Tan SK, Yeoh E. Dissecting the interaction between COVID-19 and diabetes mellitus. J Diabetes Investig 2020;11:1104-14. [PMID: 32558211 DOI: 10.1111/jdi.13326] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
3 Chen HJ, Tas SW, de Winther MPJ. Type-I interferons in atherosclerosis. J Exp Med 2020;217:e20190459. [PMID: 31821440 DOI: 10.1084/jem.20190459] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
4 Pang H, Luo S, Huang G, Xia Y, Xie Z, Zhou Z. Advances in Knowledge of Candidate Genes Acting at the Beta-Cell Level in the Pathogenesis of T1DM. Front Endocrinol (Lausanne) 2020;11:119. [PMID: 32226409 DOI: 10.3389/fendo.2020.00119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
5 Iwata Y, Matsuhashi N, Takahashi T, Suetsugu T, Fukada M, Yasufuku I, Imai T, Tanahashi T, Matsui S, Imai H, Tanaka Y, Yamaguchi K, Yoshida K. Diabetic ketoacidosis caused by fulminant type 1 diabetes during adjuvant chemotherapy for colon cancer: A case report. Mol Clin Oncol. 2019;11:189-191. [PMID: 31281655 DOI: 10.3892/mco.2019.1862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
6 Lombardi A, Tsomos E, Hammerstad SS, Tomer Y. Interferon alpha: The key trigger of type 1 diabetes. J Autoimmun. 2018;94:7-15. [PMID: 30115527 DOI: 10.1016/j.jaut.2018.08.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
7 Newby BN, Mathews CE. Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment. Front Endocrinol (Lausanne) 2017;8:232. [PMID: 28959234 DOI: 10.3389/fendo.2017.00232] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
8 Nishida T. Diagnosis and Clinical Implications of Diabetes in Liver Cirrhosis: A Focus on the Oral Glucose Tolerance Test. J Endocr Soc 2017;1:886-96. [PMID: 29264539 DOI: 10.1210/js.2017-00183] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
9 Lombardi A, Tomer Y. Interferon alpha impairs insulin production in human beta cells via endoplasmic reticulum stress. J Autoimmun 2017;80:48-55. [PMID: 28238527 DOI: 10.1016/j.jaut.2017.02.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 40] [Article Influence: 6.4] [Reference Citation Analysis]
10 Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne). 2015;6:134. [PMID: 26441826 DOI: 10.3389/fendo.2015.00134] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 6.7] [Reference Citation Analysis]
11 Zornitzki T, Malnick S, Lysyy L, Knobler H. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol 2015; 21(1): 233-239 [PMID: 25574096 DOI: 10.3748/wjg.v21.i1.233] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
12 Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A, Fabiani S, Marchi S, Ferri C, Ferrannini E, Fallahi P. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes 2014; 5(5): 586-600 [PMID: 25317237 DOI: 10.4239/wjd.v5.i5.586] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
13 Hellesen A, Edvardsen K, Breivik L, Husebye ES, Bratland E. The effect of types I and III interferons on adrenocortical cells and its possible implications for autoimmune Addison's disease. Clin Exp Immunol 2014;176:351-62. [PMID: 24666275 DOI: 10.1111/cei.12291] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
14 Mavragani CP, Niewold TB, Chatzigeorgiou A, Danielides S, Thomas D, Kirou KA, Kamper E, Kaltsas G, Crow MK. Increased serum type I interferon activity in organ-specific autoimmune disorders: clinical, imaging, and serological associations. Front Immunol 2013;4:238. [PMID: 23966997 DOI: 10.3389/fimmu.2013.00238] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
15 Alsabbagh ME, Eisa N, Alraiyes AH, Alraies MC. Chronic hepatitis C therapy: a rare complication revisited. BMJ Case Rep. 2013;2013:bcr2013200514. [PMID: 23893287 DOI: 10.1136/bcr-2013-200514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
16 Kawazoe T, Araki M, Lin Y, Ogawa M, Okamoto T, Yamamura T, Wakakura M, Murata M. New-onset type 1 diabetes mellitus and anti-aquaporin-4 antibody positive optic neuritis associated with type 1 interferon therapy for chronic hepatitis C. Intern Med 2012;51:2625-9. [PMID: 22989839 DOI: 10.2169/internalmedicine.51.7771] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
17 McCall KD, Schmerr MJ, Thuma JR, James CB, Courreges MC, Benencia F, Malgor R, Schwartz FL. Phenylmethimazole suppresses dsRNA-induced cytotoxicity and inflammatory cytokines in murine pancreatic beta cells and blocks viral acceleration of type 1 diabetes in NOD mice. Molecules 2013;18:3841-58. [PMID: 23535518 DOI: 10.3390/molecules18043841] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
18 Stinton LM, Myers RP, Coffin CS, Fritzler MJ. Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection. BMC Gastroenterol 2013;13:50. [PMID: 23506439 DOI: 10.1186/1471-230X-13-50] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
19 Vergani D, Mieli-Vergani G. Autoimmune manifestations in viral hepatitis. Semin Immunopathol. 2013;35:73-85. [PMID: 23010889 DOI: 10.1007/s00281-012-0328-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
20 Ranganathan R, Janarthanan K, Rajasekaran S. Onset of Type 1 Diabetes Mellitus During Pegylated-interferon Alfa and Ribavirin Therapy for Chronic Hepatitis C Virus Infection. J Clin Exp Hepatol 2012;2:86-7. [PMID: 25755410 DOI: 10.1016/S0973-6883(12)60089-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Oka R, Hiroi N, Shigemitsu R, Sue M, Oshima Y, Yoshida-Hiroi M. Type 1 Diabetes Mellitus Associated with Pegylated Interferon-α Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature Review. Clin Med Insights Endocrinol Diabetes. 2011;4:39-45. [PMID: 22879793 DOI: 10.4137/cmed.s7815] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
22 Nakamura K, Kawasaki E, Imagawa A, Awata T, Ikegami H, Uchigata Y, Kobayashi T, Shimada A, Nakanishi K, Makino H, Maruyama T, Hanafusa T; Research Committee on Type 1 Diabetes of the Japan Diabetes Society. Type 1 diabetes and interferon therapy: a nationwide survey in Japan. Diabetes Care 2011;34:2084-9. [PMID: 21775762 DOI: 10.2337/dc10-2274] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
23 Howard AA, Hoover DR, Anastos K, Wu X, Shi Q, Strickler HD, Cole SR, Cohen MH, Kovacs A, Augenbraun M, Latham PS, Tien PC. The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2010;54:152-9. [PMID: 20190642 DOI: 10.1097/QAI.0b013e3181d0c911] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
24 Jabri B, Sollid LM. Tissue-mediated control of immunopathology in coeliac disease. Nat Rev Immunol. 2009;9:858-870. [PMID: 19935805 DOI: 10.1038/nri2670] [Cited by in Crossref: 202] [Cited by in F6Publishing: 192] [Article Influence: 15.5] [Reference Citation Analysis]
25 Lv YY, Shi BY, Guo H. Abrupt onset of type 1 diabetes mellitus during recombinant interferon-alpha 2b therapy in a patient with chronic hepatitis B. World J Gastroenterol 2008; 14(29): 4713-4715 [PMID: 18698691 DOI: 10.3748/wjg.14.4713] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
26 Stava CJ, Jimenez C, Vassilopoulou-Sellin R. Endocrine sequelae of cancer and cancer treatments. J Cancer Surviv 2007;1:261-74. [PMID: 18648961 DOI: 10.1007/s11764-007-0038-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
27 Soultati AS, Dourakis SP, Alexopoulou A, Deutsch M, Archimandritis AJ. Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C. World J Gastroenterol 2007; 13(8): 1292-1294 [PMID: 17451219 DOI: 10.3748/wjg.v13.i8.1292] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
28 Chan WB, Chow CC, Cockram CS. Interferon alpha treatment and endocrine disease. J R Soc Med 2003;96:481-5. [PMID: 14519723 DOI: 10.1258/jrsm.96.10.481] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis]
29 Wang J, Schreiber RD, Campbell IL. STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-alpha in the central nervous system. Proc Natl Acad Sci U S A 2002;99:16209-14. [PMID: 12461178 DOI: 10.1073/pnas.252454799] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 2.1] [Reference Citation Analysis]
30 Strader DB. Understudied populations with hepatitis C. Hepatology. 2002;36:S226-S236. [PMID: 12407598 DOI: 10.1002/hep.1840360729] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
31 Strader DB. Understudied populations with hepatitis C. Hepatology 2002;36:S226-36. [PMID: 12407598 DOI: 10.1053/jhep.2002.36991] [Cited by in Crossref: 9] [Cited by in F6Publishing: 26] [Article Influence: 0.5] [Reference Citation Analysis]
32 Mofredj A, Howaizi M, Grasset D, Licht H, Loison S, Devergie B, Demontis R, Cadranel JF. Diabetes mellitus during interferon therapy for chronic viral hepatitis. Dig Dis Sci. 2002;47:1649-1654. [PMID: 12141831 DOI: 10.1023/A:1015852110353] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
33 Nishiguchi S, Shiomi S, Kurooka H, Iwata Y, Sasaki N, Tamori A, Habu D, Takeda T, Kawabe J, Ochi H. Randomized trial assessing gastric emptying in patients with chronic hepatitis C during interferon-alpha or -beta therapy and effect of cisapride. Dig Dis Sci 2002;47:73-8. [PMID: 11837736 DOI: 10.1023/a:1013263403675] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
34 Gervais A, Boyer N, Marcellin P. Tolerability of treatments for viral hepatitis. Drug Saf 2001;24:375-84. [PMID: 11419564 DOI: 10.2165/00002018-200124050-00004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
35 Wesche B, Jaeckel E, Trautwein C, Wedemeyer H, Falorni A, Frank H, von zur Mühlen A, Manns MP, Brabant G. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001;48:378-83. [PMID: 11171829 DOI: 10.1136/gut.48.3.378] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 2.2] [Reference Citation Analysis]
36 Fritzsch J, Krug J, Heberling HJ. [Interferon therapy and autoimmunity]. Med Klin (Munich) 1997;92:265-72. [PMID: 9244832 DOI: 10.1007/BF03045081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
37 Falaschi P, Martocchia A, D’Urso R, Proietti A. Subacute thyroiditis during interferon-alpha therapy for chronic hepatitis C. J Endocrinol Invest. 1997;20:24-28. [PMID: 9075068 DOI: 10.1007/bf03347968] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
38 Imagawa A, Itoh N, Hanafusa T, Waguri M, Kuwajima M, Matsuzawa Y. Antibodies to glutamic acid decarboxylase induced by interferon-alpha therapy for chronic viral hepatitis. Diabetologia 1996;39:126. [PMID: 8720616 DOI: 10.1007/BF00400426] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
39 di Cesare E, Previti M, Russo F, Brancatelli S, Ingemi MC, Scoglio R, Mazzù N, Cucinotta D, Raimondo G. Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis. Dig Dis Sci. 1996;41:1672-1677. [PMID: 8769300 DOI: 10.1007/bf02087923] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
40 Campbell S, Mclaren EH, Danesh BJ. Rapidly reversible increase in insulin requirement with interferon. BMJ. 1996;313:92. [PMID: 8688762 DOI: 10.1136/bmj.313.7049.92a] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
41 D'Amico E, Paroli M, Fratelli V, Palazzi C, Barnaba V, Callea F, Consoli G. Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection. Dig Dis Sci 1995;40:2113-6. [PMID: 7587775 DOI: 10.1007/BF02208992] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 0.9] [Reference Citation Analysis]
42 Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf. 1994;10:115-150. [PMID: 7516663 DOI: 10.2165/00002018-199410020-00003] [Cited by in Crossref: 177] [Cited by in F6Publishing: 143] [Article Influence: 6.3] [Reference Citation Analysis]